标题
Biomarker enrichment strategies: matching trial design to biomarker credentials
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume 11, Issue 2, Pages 81-90
出版商
Springer Nature
发表日期
2013-11-26
DOI
10.1038/nrclinonc.2013.218
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration
- (2013) Lisa M McShane et al. BMC Medicine
- Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer
- (2013) A. Amatu et al. CLINICAL CANCER RESEARCH
- Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers
- (2013) Daniel J Sargent et al. Clinical Trials
- Phase III Clinical Trials That Integrate Treatment and Biomarker Evaluation
- (2013) Boris Freidlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Ixabepilone or Paclitaxel Plus Carboplatin in Patients With Non–Small-Cell Lung Cancer Prospectively Stratified by Beta-3 Tubulin Status
- (2013) Martin J. Edelman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819
- (2012) M. W. Redman et al. CLINICAL CANCER RESEARCH
- Bridging the Gap: Moving Predictive and Prognostic Assays from Research to Clinical Use
- (2012) P. M. Williams et al. CLINICAL CANCER RESEARCH
- Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer
- (2012) David R. Spigel et al. Clinical Lung Cancer
- Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes
- (2012) Scott D. Ramsey et al. Contemporary Clinical Trials
- International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1
- (2012) Giorgio V. Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Adjuvant Chemotherapy: A Good Idea That Needs to Be Proven!
- (2012) Daniel F. Hayes JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial Designs With Biomarkers
- (2012) Boris Freidlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- A two-stage Bayesian design for co-development of new drugs and companion diagnostics
- (2012) Stella Wanjugu Karuri et al. STATISTICS IN MEDICINE
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enrichment of Clinical Study Populations
- (2010) R Temple CLINICAL PHARMACOLOGY & THERAPEUTICS
- A threshold sample-enrichment approach in a clinical trial with heterogeneous subpopulations
- (2010) Aiyi Liu et al. Clinical Trials
- HER2and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial
- (2010) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
- (2010) Marc Peeters et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Clinical Trials With Biomarkers: Design Issues
- (2010) B. Freidlin et al. JNCI-Journal of the National Cancer Institute
- Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
- (2010) Roy S Herbst et al. LANCET ONCOLOGY
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
- (2010) Federico Cappuzzo et al. LANCET ONCOLOGY
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection
- (2009) Antonio Jimeno et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges
- (2009) Sumithra J. Mandrekar et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
- (2009) R. M. Simon et al. JNCI-Journal of the National Cancer Institute
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Use of Genomics in Clinical Trial Design
- (2008) R. Simon CLINICAL CANCER RESEARCH
- HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer
- (2008) Soonmyung Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation